Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts

Neuro-Oncology

Volumn 15, Issue 2, 2013, Pages 189-197

  Chen, Pin Yuan ^a,b   Ozawa, Tomoko ^b   Drummond, Daryl C ^c   Kalra, Ashish ^c   Fitzgerald, Jonathan B ^c   Kirpotin, Dmitri B ^c   Wei, Kuo Chen ^b   Butowski, Nicholas ^a   Prados, Michael D ^a   Berger, Mitchel S ^a   Forsayeth, John R ^a   Bankiewicz, Krystof ^a   James, C David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

Convection enhanced delivery; Glioblastoma; Irinotecan; Liposome; Xenograft

Indexed keywords

IRINOTECAN; MM 398; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; INTRACRANIAL TUMOR; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; CONVECTION; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; FEMALE; GLIOBLASTOMA; HISTORY, ANCIENT; HUMANS; IMMUNOENZYME TECHNIQUES; INJECTIONS, INTRAPERITONEAL; LIPOSOMES; MICE; MICE, NUDE; NANOPARTICLES; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875693729     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos305     Document Type: Article

References (26)

1. Noble CO, Krauze MT, Drummond DC, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: Pharmacology and efficacy. Cancer Res. 2006;66:2801-2806.
2. Saito R, Krauze MT, Noble CO, et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol. 2006;8:205-214. (Pubitemid 46542645)
3. Yamashita Y, Krauze MT, Kawaguchi T, et al. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol. 2007;9:20-28. (Pubitemid 46543485)
4. Krauze MT, Noble CO, Kawaguchi T, et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and Pegylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol. 2007;9:393-403.
5. Serwer LP, Noble CO, Michaud K, et al. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro Oncol. 2011;13:1288-1295.
6. Riondel J, Jacrot M, Fessi H, et al. Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice. In Vivo. 1992;6:23-27.
7. Sharma US, Sharma A, Chau RI, Straubinger RM. Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res. 1997;14:992-998. (Pubitemid 27371396)
8. GrahnAY, Bankiewicz KS, Dugich-Djordjevic M, et al.Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: Initial experience. J Neurooncol. 2009;95:185-197.
9. Serwer LP, James CD. Challenges in drug delivery to tumors of the central nervous system: An overview of pharmacological and surgical considerations. Adv Drug Deliv Rev. 2012;64:590-597.
10. de Vries NA, Beijnen JH, Boogerd W, van Tellingen O. Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev Neurother. 2006;6:1199-1209. (Pubitemid 44231977)
11. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA. 1994;91:2076-2080. (Pubitemid 24092045)
12. Mamot C, Nguyen JB, Pourdehnad M, et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol. 2004;68:1-9. (Pubitemid 39137344)
13. Dickinson PJ, LeCouteur RA, Higgins RJ, et al. Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: Laboratory investigation. J Neurosurg. 2008;108:989-998. (Pubitemid 351656848)
14. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro-Oncol. 2009;12:80-91.
15. Drummond DC, Noble CO, Guo Z, et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66:3271-3277.
16. Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in Vivo and in Vitro Fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer. 2004;39:29-36. (Pubitemid 37475250)
17. Giannini C, Sarkaria JN, Saito A, et al. Patient Tumor EGFR and PDGFRA Gene Amplifications Retained in an Invasive Intracranial Xenograft Model of GBM. Neuro-Oncol. 2005;7:164-176. (Pubitemid 40590516)
18. Dinca EB, Sarkaria JN, Schroeder MA, et al. Bioluminescence Monitoring of Intracranial Glioblastoma Xenograft Response to Primary and Salvage Temozolomide Therapy. J Neurosurg. 2007;107:610-616. (Pubitemid 47451046)
19. Ozawa T, James CD. Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging. J Vis Exp. 2010;41: Doi:pii: 1986.3791/1986.
20. Serwer L, Hashizume R, Ozawa T, James CD. Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models. J Vis Exp. 2010;42: Doi:pii: 1992. 10.3791/1992
21. Yin D, Forsayeth J, Bankiewicz KS. Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods. 2010;187:46-51.
22. Ozawa T, Faddegon BA, Hu LJ, et al. Response of intracerebral human glioblastoma xenografts to multi-fraction radiation exposures. Int J Radiat Oncol Biol Phys. 2006;66:263-270. (Pubitemid 44175674)
23. Verhaak RGW, Hoadley KA, Purdom E, et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell. 2010;17:98-110.
24. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an Orthotopic Xenograft Model for Assessing the Effect of EGFR Amplification on Glioblastoma Radiation Response. Clin Cancer Res. 2006;12: 2264-2271.
25. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
26. Chamberlain M. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol. 2011;5:117-129.